Deep & Frequent Phenotyping Study (DFP)
The DFP study tracks biological and cognitive markers of Alzheimer's disease across time to find the best combination to detect disease change.
Title: Deep and Frequent Phenotyping; Combinatorial Biomarkers for Dementia Experimental Medicine
Short title: Deep and Frequent Phenotyping Study
Sponsor: University of Oxford
Chief Investigator: Dr Vanessa Raymont, University of Oxford
Edinburgh PI: Prof Craig Ritchie/Dr Catherine Pennington
Ethics ref: 17/SC/0315
Funder: National Institute for Health Research and Medical Research Council
Dates (estimated): August 2021 - March 2025
Synopsis: DFP will combine established and novel markers of Alzheimer's disease to find the best set of markers that detect disease change in people who have and don't have risk factors, such as brain amyloid, for Alzheimer's disease. This data will help inform future clinical research studies on the best methods to use for their studies - saving time and increasing efficiency.
The study will recruit 250 people nationally across six sites at Edinburgh, South London, West London, Newcastle, Manchester, and study sponsor, the University of Oxford.
Study participants will undergo extensive (deep) and repeated (frequent) biological and cognitive testing including genetics, amyloid testing, memory and thinking tasks, brain imaging, ophthalmology, electroencephalography, magnetoencephalography, and gait analysis.
Aims: The study aims to find the best combination of markers to detecting Alzheimer's disease early. The results will influence the design of future trials in dementia research.
Links and Publications: Published papers from the DFP study on Pubmed.
- Video: Dr Vanessa Raymont talks about DFP
- Dr Vanessa Raymont is chief investigator of the Deep and Frequent Phenotyping (DFP) study and a senior clinical researcher in Oxford University's Department of Psychiatry. At Dementias Platform UK's five-year celebration event, Vanessa talked about why DFP is unique in the quest to know more about the earliest stages of Alzheimer's disease.